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Abstract
　　 Most of anticancer agents used by the chemotherapy of cancer act in the division process of the cel 
and show an efect, and cause side efects such as a drop and nausea of the immunity, the hair loss, which 
reduce the quality of life （QOL） of the patient. In this article, the history and current status of oncolytic 
viruses, which are cancer therapeutic agents that do not cause these side efects and attracting the most 
attention now are introduced. An oncolytic virus is a virus that preferentialy infects and kils cancer cels. 
As the infected cancer cels are destroyed by oncolysis, they release new infectious virus particles to 
destroy the remaining tumor. Oncolytic viruses are thought not only to cause direct destruction of the 
tumour cels, but also to stimulate host anti-tumour immune responses. In 2015 the first oncolytic virus 
was approved by FDA as the cancer therapeutic agent. The clinical trial using the oncolytic virus is 
pushed forward now in Japan. It is hoped that the virus therapy for cancer treatment with tumor 
solubility virus greatly develops from now on.





Oncolytic Viruses as Cancer Therapeutic agents
～Current Status of Oncolytic Viruses～
Yusuke Eto, Katsuyuki Nagai1
九州保健福祉大学薬学部薬学科　〒882-8508　宮崎県延岡市吉野町1714-1
Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Kyushu University of Health and Welfare













































































































































































































⚑）Elizabeth Kely, Stephen J Russel, History of 
Oncolytic Viruses:Genesis to Genetic Engineering, 




⚓）U.S.FOOD & DRUG, FDA approves first-of-its-kind

























Suspension for Injection,https://www.imlygic.com/ 
（2015）.
